Pharma: Expand Sales of Generic Drugs and Accelerate Biosimilar Development to Drive Growth

Meiji Holdings Co., Ltd. Financial Results for FYE March 2018and New Medium-term Business Plan

	TOP

	Financial Results for FYE March 2018 and New Medium-term Business Plan

	Agenda

	1. Overview of STEP UP 17

	2. The Meiji Group 2026 Vision

	3. The New Medium-term Business Plan Key Strategies Food: Expanding Yogurt, Chocolate, and Nutritional Products Food: Cultivate Future Growth Drivers Pharma: Maximize Product Value in Core Domains and Enhance Presence Pharma: Expand Sales of Generic Drugs and Accelerate Biosimilar Development to Drive Growth Food: Launch High Value-added Products, Invest Intensely in Overseas Business Pharma: Expand CMO/CDMO Business at Medreich Food: Continue Structural Reforms to Improve Productivity Food: Improve Profitability in Milk Business Pharma: Structural Reform and Platform Development to Grow Income from Overseas Agricultural Chemicals and Veterinary Drug Business KPIs - The New Medium-term Business Plan (1) KPIs - The New Medium-term Business Plan (2) Use of Cash Flows

	4. Outlook for the FYE March 2019

	Appendix: Financial data

	Appendix: Topics

	Back cover

Pharma: Expand Sales of Generic Drugs and Accelerate Biosimilar Development to Drive Growth

Prev. Page

Next Page

Download the PDF

Generic drug

• Anticipating two NHI drug price revisions by FYE March 2021

• Achieve net sales of JPY 65 billion despite serious impact of NHI drug price revisions

Performance of specialty generic drug business is the key

• Serious impact of NHI drug price revisions

• Our strength - Supply low-cost, high-quality products stably

• Accelerate CMO/CDMO business - Develop as new business

• Production sites - Medreich and other overseas subsidiaries

Medreich

• Large-scale production capacity of 3 billion tablets for Japanese market

• Expand as profitable business using facility efficiently for Japanese market

DM Bio, Korea

• Promote biosimilar development projects